Completed NA INTERVENTIONAL 2-arm NCT05395702

Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia

Pilot Single-center Open Study of the Effect of Ingaron on the Efficacy and Resistance to Antibiotics in Antibacterial Therapy in Patients With Community-acquired Pneumonia

Sponsor: SPP Pharmaclon Ltd.

Conditions Community-acquired Pneumonia

Interventions Interferon-Gamma

Updated 4 times since 2022 Last updated: May 24, 2022 Started: May 12, 2017 Primary completion: Jul 27, 2018 Completion: May 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Community-acquired Pneumonia, this trial is completed. The trial is conducted by SPP Pharmaclon Ltd. and has accumulated 4 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SPP Pharmaclon Ltd.

Data source: SPP Pharmaclon Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia